Comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190 vs 3q26 Microduplication Syndrome C4755319
Clinical comparison between 3 Phosphoglycerate Dehydrogenase Deficiency and 3q26 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
A rare metabolic disorder impairing the body's ability to produce serine, an essential amino acid. It primarily affects the nervous system, causing developmental delay, seizures, and movement difficulties. Management includes serine supplementation and anticonvulsants as needed.
3q26 Microduplication Syndrome C4755319
A genetic condition involving extra genetic material at chromosome 3q26, which can cause developmental delays and other features depending on specific genes involved.
6 comparison axes
Onset
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
0-5
3q26 Microduplication Syndrome C4755319
0-null
Onset patterns differ
Severity
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
severe
3q26 Microduplication Syndrome C4755319
moderate
Different severity levels
Chronic
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
Chronic
3q26 Microduplication Syndrome C4755319
Chronic
Differing course
Communicable
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
No
3q26 Microduplication Syndrome C4755319
No
Different transmission
Body System
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3q26 Microduplication Syndrome C4755319
congenital
Same/different system
Category
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3q26 Microduplication Syndrome C4755319
genetic
Different category
Bottom line
3-phosphoglycerate-dehydrogenase-deficiency-C0580190 and 3q26-microduplication-syndrome-C4755319 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3q26 Microduplication Syndrome C4755319 | Discriminating power |
|---|---|---|---|
| Seizures | Often prominent with developmental delay and movement difficulty. | Not established; may occur only in some individuals. | Moderate |
| Developmental delay | Typically early and often severe, mainly neurologic. | Possible, with severity and features depending on duplicated genes. | Low |
| Movement difficulty | Described as a characteristic neurologic feature. | Not specifically established from available data. | Moderate |
When to favor each condition
Choose 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 when
Infantile neurologic disease with seizures
Fits the described serine-synthesis disorder better than a nonspecific duplication.
Moderate
Suspected metabolic encephalopathy
Impaired serine production points toward biochemical evaluation.
High
Need for targeted metabolic treatment
Serine supplementation and seizure treatment may be considered by clinicians.
Moderate
Choose 3q26 Microduplication Syndrome C4755319 when
Congenital developmental disorder without metabolic clues
A chromosomal cause is more plausible when features are variable.
Moderate
Family or prenatal genetic concern
Microduplication is identified by genomic testing rather than biochemistry.
High
Phenotype depends on gene content
Available evidence does not define one uniform syndrome.
High
How key tests differ
| Test | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3q26 Microduplication Syndrome C4755319 | Interpretation |
|---|---|---|---|
| Plasma or CSF amino acids | Low serine may support the disorder; cutoffs are not stated here. | No characteristic amino-acid pattern is established. | An abnormal result is not itself a diagnosis and needs clinical correlation. |
| Enzyme or gene testing | PHGDH-related testing can confirm the metabolic diagnosis. | Not the primary test for a chromosomal duplication. | Use specialist genetic interpretation. |
| Chromosomal microarray | Not expected to identify the metabolic enzyme defect. | May detect extra material at 3q26. | Gene content and clinical context determine significance. |
Prognosis comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
- Outcome
- Often severe chronic neurologic disease; exact outcomes are not established here.
- Factors
- Seizure burden, developmental impairment, and response to clinician-directed care.
3q26 Microduplication Syndrome C4755319
- Outcome
- Generally described as moderate, but individual outcome is uncertain.
- Factors
- Duplication size, gene content, and associated findings.
Time frame: Both are chronic; onset is early for the metabolic disorder and congenital for the duplication.
Neither comparison establishes mortality or a uniform prognosis.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic impairment | Developmental delay, seizures, and movement difficulty are described. Developmental delay is possible; other neurologic effects are not fixed. Severity should be assessed individually. |
| Treatment-related issues | Supplementation and anticonvulsants may require monitoring. No specific treatment complication is established. Do not infer doses or outcomes from these data. |
| Associated congenital anomalies | Not established as a defining feature. Possible but depend on the duplicated genes. Avoid assuming a standard malformation pattern. |
Patient education highlights
- HighDifferent causes
One is a metabolic serine disorder; the other is extra chromosomal material.
- HighTesting
Biochemical and genomic tests answer different questions and require clinician review.
- MediumVariability
The duplication phenotype can vary, so predictions should remain cautious.